Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.amiorganics.com | |
Market Cap | 3,160.37 Cr. | |
Enterprise Value(EV) | 3,135.13 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 21.26 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 41.15 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 147.59 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 5.93 | Calculated using Price: 874.80 |
Dividend Yield | 0.35 | Period Ending 2022-03 |
No. of Shares Subscribed | 3.64 Cr. | 36,437,062 Shares |
FaceValue | 10 | |
Company Profile | ||
The company is one of the leading research and development driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical ingredients (API) for New Chemical Entities, and material for agrochemicals and fine chemicals. |
1 Day |
|
-2.16% |
1 Week |
|
-0.38% |
1 Month |
|
-8.85% |
3 Month |
|
-6.69% |
6 Month |
|
-13.33% |
1 Year |
|
-13.79% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
7 years | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 46.43 | 36.44 | 39.03 | 33.73 | 28.31 | 39.63 | 21.28 | |
Return on Capital Employed (%) | 35.54 | 35.91 | 38.24 | 33.80 | 26.25 | 33.01 | 24.05 | |
Return on Assets (%) | 13.87 | 12.04 | 13.99 | 12.64 | 12.34 | 16.74 | 13.42 |
Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 27 | 39 | 58 | 82 | 112 | 167 | 522 | 544 | |
Non Curr. Liab. | 15 | 15 | 33 | 25 | 25 | 80 | 7 | 8 | |
Curr. Liab. | 49 | 55 | 65 | 106 | 95 | 166 | 129 | 142 | |
Minority Int. | |||||||||
Equity & Liab. | 91 | 109 | 155 | 213 | 232 | 413 | 659 | 695 | |
Non Curr. Assets | 25 | 42 | 66 | 89 | 111 | 191 | 223 | 263 | |
Curr. Assets | 66 | 66 | 87 | 124 | 121 | 216 | 429 | 432 | |
Misc. Exp. not W/O | 0 | 0 | 2 | 6 | 7 | ||||
Total Assets | 91 | 109 | 155 | 213 | 232 | 413 | 659 | 695 |
Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 154 | 160 | 188 | 239 | 240 | 341 | 520 | 574 | |
Other Income | 3 | 0 | 3 | 0 | 3 | 1 | 3 | 5 | |
Total Income | 157 | 160 | 191 | 239 | 242 | 342 | 523 | 579 | |
Total Expenditure | -136 | -137 | -158 | -196 | -199 | -260 | -415 | -466 | |
PBIDT | 21 | 23 | 33 | 42 | 44 | 82 | 108 | 112 | |
Interest | -3 | -3 | -3 | -5 | -6 | -6 | -6 | -2 | |
Depreciation | -1 | -1 | -2 | -3 | -4 | -4 | -10 | -12 | |
Taxation | -5 | -7 | -10 | -12 | -7 | -18 | -20 | -20 | |
Exceptional Items | |||||||||
PAT | 13 | 12 | 19 | 23 | 27 | 54 | 72 | 77 | |
Minority Interest | |||||||||
Share Associate | |||||||||
Other Related Items | |||||||||
Consolidated Net Profit | 13 | 12 | 19 | 23 | 27 | 54 | 72 | 77 | |
Adjusted EPS | 84 | 80 | 123 | 22 | 26 | 6 | 20 | 21 |
Particulars | 7 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 10 | 29 | 8 | 15 | 27 | 28 | -9 | |
Cash Fr. Inv. | -14 | -19 | -25 | -21 | -24 | -101 | -124 | |
Cash Fr. Finan. | 4 | -7 | 15 | 6 | 0 | 72 | 140 | |
Net Change | 0 | 3 | -2 | 0 | 3 | -1 | 8 | |
Cash & Cash Eqvt | 0 | 3 | 1 | 0 | 4 | 3 | 10 |
Sat, 04 Feb 2023
Board Meeting Outcome for Outcome Of Board Meeting Held On February 4 2023 The Board of Directors of the Company at their meeting held on Saturday February 4 2023 inter alia considered & approved Unaudited Standalone & Consolidated Financial Results of the Company for the third quarter & nine months ended December 31 2022. |
Sat, 04 Feb 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release We are enclosing herewith a Press Release discussing the third quarter & nine months ended financial results as on December 31 2022. |
Sat, 04 Feb 2023
Unaudited Standalone And Consolidated Financial Results For Third Quarter And Nine Months Ended December 31 2022 We would like to inform that the Board of Directors at its meeting held on February 4 2023 inter alia considered and approved the Unaudited Standalone and consolidated Financial Results for the third quarter and nine months ended December 31 2022 as recommended by the Audit Committee. |
Fri, 03 Feb 2023 |
|
|
|
|
|